The full text of this article hosted at iucr.org is unavailable due to technical difficulties.

Research Article

Scalable culture of human induced pluripotent cells on microcarriers under xeno‐free conditions using single‐use vertical‐wheel™ bioreactors

Carlos AV Rodrigues

Corresponding Author

E-mail address: carlos.rodrigues@tecnico.ulisboa.pt

Department of Bioengineering and iBB‐Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal

The Discoveries Centre for Regenerative and Precision Medicine, Lisbon Campus, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal

Correspondence to: CAV Rodrigues, Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Av. Rovisco Pais, 1049‐001, Lisbon, Portugal. E‐mail:

carlos.rodrigues@tecnico.ulisboa.pt

Search for more papers by this author
Teresa P Silva

Department of Bioengineering and iBB‐Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal

The Discoveries Centre for Regenerative and Precision Medicine, Lisbon Campus, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal

Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal

Search for more papers by this author
Diogo ES Nogueira

Department of Bioengineering and iBB‐Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal

The Discoveries Centre for Regenerative and Precision Medicine, Lisbon Campus, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal

Search for more papers by this author
Tiago G Fernandes

Department of Bioengineering and iBB‐Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal

The Discoveries Centre for Regenerative and Precision Medicine, Lisbon Campus, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal

Search for more papers by this author
Yas Hashimura

PBS Biotech, Inc., Camarillo, CA, USA

Search for more papers by this author
Robin Wesselschmidt

PBS Biotech, Inc., Camarillo, CA, USA

Search for more papers by this author
Maria Margarida Diogo

Department of Bioengineering and iBB‐Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal

The Discoveries Centre for Regenerative and Precision Medicine, Lisbon Campus, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal

Search for more papers by this author
Brian Lee

PBS Biotech, Inc., Camarillo, CA, USA

Search for more papers by this author
Joaquim MS Cabral

Department of Bioengineering and iBB‐Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal

The Discoveries Centre for Regenerative and Precision Medicine, Lisbon Campus, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal

Search for more papers by this author
First published: 11 June 2018

Abstract

BACKGROUND

Human induced pluripotent stem cells (hiPSC) are expected to become powerful tools for disease modelling, for the discovery and testing of new drugs and, ultimately, for regenerative therapies. The success of these applications depends on the development of scalable bioprocesses capable of generating large numbers of hiPSC and derivatives.

RESULTS

In this work, the novel vertical‐wheel single‐use bioreactors were used for the first time for the expansion of hiPSC under xeno‐free conditions. Cultures were performed on microcarriers in two different scales of vessels (100 and 500 mL with 80 and 300 mL working volumes, respectively), leading to maximum cell densities up to 1.21 ± 0.02 × 106 cells mL−1 and volumetric productivities of 2.01 ± 0.04 × 105 cells mL−1 day−1. The pluripotency as well as a normal karyotype were maintained after cell expansion. Consistency of the processes was confirmed with a different hiPSC line, which is an important aspect for a personalized medicine approach.

CONCLUSION

The results here described demonstrate the feasibility of scalable production of hiPSC in a microcarrier‐based system using vertical‐wheel bioreactors. The protocols developed in this study provide a Good Manufacturing Practices (GMP)‐compliant system for hiPSC manufacturing which may be an important step towards the successful implementation of hiPSC‐based products. © 2018 Society of Chemical Industry